|
1
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Siegel RL and Jemal A: Lung
cancer statistics. Adv Exp Med Biol. 893:1–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miller KD, Nogueira L, Devasia T, Mariotto
AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment
and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang M, Herbst RS and Boshoff C: Toward
personalized treatment approaches for non-small-cell lung cancer.
Nat Med. 27:1345–1356. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Banfill K, Giuliani M, Aznar M, Franks K,
McWilliam A, Schmitt M, Sun F, Vozenin MC and Faivre Finn C; IASLC
Advanced Radiation Technology committee, : Cardiac toxicity of
thoracic radiotherapy: Existing evidence and future directions. J
Thorac Oncol. 16:216–227. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bentzen SM: Preventing or reducing late
side effects of radiation therapy: Radiobiology meets molecular
pathology. Nat Rev Cancer. 6:702–713. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wennerberg E, Mukherjee S, Spada S, Hung
C, Agrusa CJ, Chen C, Valeta-Magara A, Rudqvist NP, Van Nest SJ,
Kamel MK, et al: Expression of the mono-ADP-ribosyltransferase ART1
by tumor cells mediates immune resistance in non-small cell lung
cancer. Sci Transl Med. 14:eabe81952022. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Horvath L, Thienpont B, Zhao L, Wolf D and
Pircher A: Overcoming immunotherapy resistance in non-small cell
lung cancer (NSCLC)-novel approaches and future outlook. Mol
Cancer. 19:1412020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Ruysscher D, Faivre-Finn C, Nackaerts
K, Jordan K, Arends J, Douillard JY, Ricardi U and Peters S:
Recommendation for supportive care in patients receiving concurrent
chemotherapy and radiotherapy for lung cancer. Ann Oncol. 31:41–49.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rinaldi M, Cauchi C and Gridelli C: First
line chemotherapy in advanced or metastatic NSCLC. Ann Oncol. 17
(Suppl 5):v64–v67. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsan DL, Lin CY, Kang CJ, Huang SF, Fan
KH, Liao CT, Chen IH, Lee LY, Wang HM and Chang JT: The comparison
between weekly and three-weekly cisplatin delivered concurrently
with radiotherapy for patients with postoperative high-risk
squamous cell carcinoma of the oral cavity. Radiat Oncol.
7:2152012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chaft JE, Rimner A, Weder W, Azzoli CG,
Kris MG and Cascone T: Evolution of systemic therapy for stages
I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin
Oncol. 18:547–557. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pignon JP, Tribodet H, Scagliotti GV,
Douillard JY, Shepherd FA, Stephens RJ, Dunant A, Torri V, Rosell
R, Seymour L, et al: Lung adjuvant cisplatin evaluation: A pooled
analysis by the LACE collaborative group. J Clin Oncol.
26:3552–3559. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun Y, Shen W, Hu S, Lyu Q, Wang Q, Wei T,
Zhu W and Zhang J: METTL3 promotes chemoresistance in small cell
lung cancer by inducing mitophagy. J Exp Clin Cancer Res.
42:652023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang D, Zhao C, Xu F, Zhang A, Jin M,
Zhang K, Liu L, Hua Q, Zhao J, Liu J, et al: Cisplatin-resistant
NSCLC cells induced by hypoxia transmit resistance to sensitive
cells through exosomal PKM2. Theranostics. 11:2860–2875. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Song JW, Zhu J, Wu XX, Tu T, Huang JQ,
Chen GZ, Liang LY, Zhou CH, Xu X and Gong LY: GOLPH3/CKAP4 promotes
metastasis and tumorigenicity by enhancing the secretion of
exosomal WNT3A in non-small-cell lung cancer. Cell Death Dis.
12:9762021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Scott KL, Kabbarah O, Liang MC, Ivanova E,
Anagnostou V, Wu J, Dhakal S, Wu M, Chen S, Feinberg T, et al:
GOLPH3 modulates mTOR signalling and rapamycin sensitivity in
cancer. Nature. 459:1085–1090. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu T, An Q, Cao XL, Yang H, Cui J, Li ZJ
and Xiao G: GOLPH3 inhibition reverses oxaliplatin resistance of
colon cancer cells via suppression of PI3K/AKT/mTOR pathway. Life
Sci. 260:1182942020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang MZ, Qiu CZ, Yu WS, Guo YT, Wang CX
and Chen ZX: GOLPH3 expression promotes the resistance of HT29
cells to 5-fluorouracil by activating multiple signaling pathways.
Mol Med Rep. 17:542–548. 2018.PubMed/NCBI
|
|
20
|
Gao Y, Yin Z, Qi Y, Peng H, Ma W, Wang R
and Li W: Golgi phosphoprotein 3 promotes angiogenesis and
sorafenib resistance in hepatocellular carcinoma via upregulating
exosomal miR-494-3p. Cancer Cell Int. 22:352022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Meng F, Li Y, Liu Q, Sun L, Wang H, Li X,
Li G and Chen F: Experimental study of camptothecin combined with
drug-eluting bead transarterial chemoembolization in the rabbit VX2
liver tumor model. Front Oncol. 12:9069712022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qi Y, Wei J and Zhang X: Requirement of
transcription factor NME2 for the maintenance of the stemness of
gastric cancer stem-like cells. Cell Death Dis. 12:9242021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fuertes MA, Alonso C and Pérez JM:
Biochemical modulation of Cisplatin mechanisms of action:
Enhancement of antitumor activity and circumvention of drug
resistance. Chem Rev. 103:645–662. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zalewska-Ziob M, Adamek B, Kasperczyk J,
Romuk E, Hudziec E, Chwalińska E, Dobija-Kubica K, Rogoziński P and
Bruliński K: Activity of antioxidant enzymes in the tumor and
adjacent noncancerous tissues of non-small-cell lung cancer. Oxid
Med Cell Longev. 2019:29018402019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu C, Liu Z, Chen Z, Xu D, Chen L, Lin H
and Shi J: A nonferrous ferroptosis-like strategy for antioxidant
inhibition-synergized nanocatalytic tumor therapeutics. Sci Adv.
7:eabj88332021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Glasauer A, Sena LA, Diebold LP, Mazar AP
and Chandel NS: Targeting SOD1 reduces experimental non-small-cell
lung cancer. J Clin Invest. 124:117–128. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Karami Fath M, Ebrahimi M, Nourbakhsh E,
Zia Hazara A, Mirzaei A, Shafieyari S, Salehi A, Hoseinzadeh M,
Payandeh Z and Barati G: PI3K/Akt/mTOR signaling pathway in cancer
stem cells. Pathol Res Pract. 237:1540102022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang
J, Zhang G, Wang X, Dong Z, Chen F and Cui H: Targeting cancer stem
cell pathways for cancer therapy. Signal Transduct Target Ther.
5:82020. View Article : Google Scholar : PubMed/NCBI
|
